Multiple Drug Resistance Bacterial Infection Treatment Market By Vector (Critical, Medium, High), By Drug Class (Cephalosporin, Beta Lactam, Beta Lactamase Inhibitors, Oxazolidinone, Cyclic Lipopeptide, Glycolipopeptides ) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on global multiple drug resistance bacterial infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries. Promising pipeline of novel antibiotics with more effective mechanism of action to counteract drug resistance by microbes will result into deep market penetration of the multiple drug resistance bacterial infection treatment market.

For the purpose of this study, the vectors studied include critical, high and medium ; drug class studied for the purpose of this research are segmented as cephalosporins, beta lactams, beta lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides and others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global multiple drug resistance bacterial infection treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players.

Multiple Drug Resistance Bacterial Infection Treatment Market

For the purpose of this study, the global multiple drug resistance bacterial infection treatment market is categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Multiple Drug Resistance Bacterial Infection Treatment Market

North America was observed as the largest market for multiple drug resistance bacterial infection treatment market in the base year 2016. According to Department of Health and Human Services of CDC report 2015 approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly due to rising prevalence of multiple drug resistance cases, evolved health infrastructure and affordable reimbursement scenario. According to the European Centre for Disease Prevention and Control approximately 25,000 deaths were associated with multidrug resistant bacterial infection; the growth is chiefly attributed due to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment, and supportive regulatory approval for launch of new antibiotics for the treatment of multiple drug resistance. Asia Pacific will be the fastest growing regional segment throughout the forecast period 2017-2025, the growth is attributed by factors like rising prevalence of geriatric population suffering with multiple drug resistance bacterial infection and increasing disposable income in these regions. Factors such as developing health infrastructure, increasing awareness regarding the judicious use of prescribed antibiotics especially in the remote areas are going to fuel the rapid growth of multiple drug resistance bacterial infection treatment market in Latin America and Middle East and Africa region in the near future.   

Choose License Type
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58597
Report Format:   PDF
Pages:   120
Rating:    4.4 (70)
Connect With Us
+1-408-641-3282
24/7 Research Support